- Home
- REX vs CAPR Comparison
REX vs CAPR Comparison
Compare REX & CAPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REX
- CAPR
- Stock Information
- Founded
- REX 1980
- CAPR 2005
- Country
- REX United States
- CAPR United States
- Employees
- REX N/A
- CAPR N/A
- Industry
- REX Major Chemicals
- CAPR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- REX Industrials
- CAPR Health Care
- Exchange
- REX Nasdaq
- CAPR Nasdaq
- Market Cap
- REX 699.5M
- CAPR 600.7M
- IPO Year
- REX N/A
- CAPR N/A
- Fundamental
- Price
- REX $49.76
- CAPR $9.67
- Analyst Decision
- REX Strong Buy
- CAPR Strong Buy
- Analyst Count
- REX 1
- CAPR 8
- Target Price
- REX $50.00
- CAPR $33.75
- AVG Volume (30 Days)
- REX 130.0K
- CAPR 3.3M
- Earning Date
- REX 05-28-2025
- CAPR 08-06-2025
- Dividend Yield
- REX N/A
- CAPR N/A
- EPS Growth
- REX N/A
- CAPR N/A
- EPS
- REX 3.24
- CAPR N/A
- Revenue
- REX $639,600,000.00
- CAPR $17,363,588.00
- Revenue This Year
- REX $3.27
- CAPR $258.96
- Revenue Next Year
- REX $17.11
- CAPR $8.02
- P/E Ratio
- REX $15.05
- CAPR N/A
- Revenue Growth
- REX N/A
- CAPR N/A
- 52 Week Low
- REX $33.45
- CAPR $3.52
- 52 Week High
- REX $52.00
- CAPR $23.40
- Technical
- Relative Strength Index (RSI)
- REX 63.93
- CAPR 45.24
- Support Level
- REX $48.54
- CAPR $6.07
- Resistance Level
- REX $50.13
- CAPR $11.58
- Average True Range (ATR)
- REX 1.22
- CAPR 1.59
- MACD
- REX -0.03
- CAPR -0.23
- Stochastic Oscillator
- REX 68.13
- CAPR 44.57
About REX REX American Resources Corporation
REX American Resources Corp operates as a holding company, which engages in investment in alternative energy and ethanol production entities. Its operating segments include Ethanol and By-Products. Its products include dried distillers grains, modified distillers grains, and non-food grade corn oil.
About CAPR Capricor Therapeutics Inc.
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.